This study is in progress, not accepting new patients
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)
Summary
- Eligibility
- for people ages 18-55 (full criteria)
- Location
- at UCLA UCSD UCSF
- Dates
- study startedcompletion around
- Principal Investigator
- by Bruce Cree (ucsf)
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Bruce Cree (ucsf)
Bruce Cree, MD, PhD, MAS is a Professor of Clinical Neurology and is the George A. Zimmermann Endowed Professor in Multiple Sclerosis in the Department of Neurology at the University of California San Francisco. Dr. Cree completed his MD and PhD in Biochemistry at UCSF. His neurology residency training was at Columbia University.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Sanofi
- ID
- NCT04458051
- Phase
- Phase 3 Multiple Sclerosis Research Study
- Study Type
- Interventional
- Participants
- About 766 people participating
- Last Updated